Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has submitted its abbreviated new drug application (ANDA) asking marketing approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% to the US Food and Drug Administration.
Subscribe to our email newsletter
Watson‘s lopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is the generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% of Alcon, which is used to treat ocular itching linked with allergic conjunctivitis.
Last week, Novartis‘ Alcon Research, Alcon Pharmaceuticals and Kyowa Hakko Kirin have sued Watson to preventthe company from commercializing its product before the expiration of US patent nos. 5,641,805, 6,995,186, and 7,402,609.